Regulatory status
Cerebrolysin is classified as an unapproved research compound. There is no FDA-approved label, indication, or dosing information for this substance.
What cerebrolysin is
Cerebrolysin is a compound that has been studied in clinical research settings but does not have an approved drug label describing its class or mechanism. No official prescribing information exists for it.
Trial footprint
A total of 42 trials involving cerebrolysin have been registered. Among the studies on record, one titled "Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease" reached completed status. Another, "Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke," also completed. A separate registry study, "Cerebrolysin REGistry Study in Stroke," was terminated before completion.
FAQ
No. Cerebrolysin does not have FDA approval and carries no official prescribing label. It is classified as an unapproved research compound.
There are 42 registered trials involving cerebrolysin. These include studies with varying statuses, from completed to terminated.
Registered trials have examined cerebrolysin in contexts such as Alzheimer's disease and ischemic stroke. These are research studies and do not indicate an approved use for any condition.
Yes. A registry study called the Cerebrolysin REGistry Study in Stroke was terminated. The available data does not specify the reason for termination.
No adverse event report data is available for cerebrolysin in the data reviewed here. This does not confirm the compound is free of side effects, only that no report data was found.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov
Updated 2026-09-19